Cytogenetic and molecular changes in myelodysplastic syndromes and their clinical significance;Zmiany cytogenetyczne i molekularne w zespołach mielodysplastycznych i ich znaczenie kliniczne

Polskie Archiwum Medycyny Wewnetrznej

Volumn 99, Issue 2, 1998, Pages 114-122

  Haus, Olga ^a,b  

^a UMK   (Poland)

^b Katedra i Klinika Hematologii   (Poland)

Author keywords

5q Syndrome; Chromosome aberrations; fms; Myelodysplastic syndromes (MDS); Prognostic significance; ras

Indexed keywords

ADULT; ARTICLE; CHROMOSOME ABERRATION; GENETICS; HUMAN; MYELODYSPLASTIC SYNDROME; PROGNOSIS;

ADULT; CHROMOSOME ABERRATIONS; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 0031991839     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Ohyashiki K., Ohyashiki J.H., Iwabuchi A., Toyama K., Clinical aspects and disease evolution in myelodysplastic syndromes. Leukemia Lymphoma, 1996, 23, 409.
2. Fenaux P., Morel P., Lai J.L.: Cytogenetics of myelodysplastic syndromes. Semin Hematol, 1996, 33, 127.
3. Verhoef G., Meeus P., Stul M. i wsp., Cytogenetic and molecular studies of the Philadelphia translocation in myelodysplastic syndromes. Cancer Genet. Cytogenet., 1992, 59, 161.
4. Yamasaki H., Era T., Asou N. i wsp.: High degree of myeloid differentiation and granulocytosis is associated with t(8;21) smoldering leukemia. Leukemia, 1995, 9, 1147.
5. Furuya T., Morgan K., Sandberg A.A.: Cytogenetic biclonality in malignant hematologic disorders. Cancer Genet. Cytogenet., 1992, 62, 25.
6. White A.D., Jacobs A.: Peripheral blood chromosome aberrations in MDS. Cancer Genet. Cytogenet., 1992, 59, 167.
7. Sole F., Prieto F., Badia L. i wsp.: Cytogenetic studies in 112 cases of untreated myelodysplastic syndromes. Cancer Genet. Cytogenet., 1992, 64, 12.
8. Noel A., Tefferi A., Pierre V., Jenkins R.B., Dewald G.W., Karyotypic analysis in primary myelodysplastic syndromes. Blood Rev., 1993, 7, 10.
9. Jotterand M., Parlier V.: Diagnostic and prognostic significance of cytogenetics in adult primary myelodysplastic syndromes. Leukemia Lymphoma, 1996, 23, 253.
10. .Johansson B., Mertens F., Heim S., Kristofferson U., Mitelman F.: Cytogenetics of secondary dysplasia (sMDS) and acute nonlymphocytic leukemia (sANLL). Eur. J. Haematol., 1991, 41, 17.
11. Tigaud I., Charrin C., Berger R., Jonveaux P., Partical deletion of the long arm of chromosome 5: A fluorescence in situ hybridization study using band-specific painting probes generated by chromosome microdissection. Cancer Genet. Cytogenet., 1996, 89, 126.
12. Pedersen B., Jensen I.M., Clinical and prognostic implications of chromosome 5q deletions: 96 high resolution studied patients. Leukemia, 1991, 5, 566.
13. van den Berghe H., Michaux L.: 5q-, twenty-five years later: A synopsis. Cancer Genet. Cytogenet., 1997, 94, 1.
14. Nagarajan L.: Molecular analysis of the 5q-chromosome. Leukemia Lymphoma, 1995, 17, 361.
15. Beretta L., Gabbav M., Berger R., Hanasch S.M , Sonenberg N.: Expression of the protein kinase PKR is modulated by IRF 1 and is reduced in 5q- associated leukemias. Oncogene, 1996, 12, 1593.
16. Boultwood J., Oscier D.G., Buckle V.J., Wainscoat J.K.S.: Loss of both CSF 1 R (FMS) alleles in patients with myelodysplasia and a chromosome 5 deletion. Proc. Natl. Acad. Sci USA, 1991, 88, 6176.
17. van den Berghe H., Cassiman J.J., David B., Fryns J.P., Michaux J.L., Sokal G.: Distinct haematological disorder with deletion of long arm of No. 5 chromosome. Nature, 1974, 251, 437.
18. Parlier V., van Melle G., Beris Ph. i wsp.: Hematologic, clinical and cytogenetic analysis in 109 patients with primary myelodysplastic syndrome. Cancer Genet. Cytogenet., 1994, 78, 219.
19. Musilova J., Michalova K., Zemanova Z., Neuwirthova R., Dohnalova A. and the Czechoslovak MDS Cooperative Study Group: karyotype at diagnosis, subsequent leukemic transformation and survival in myelodysplastic syndrome. Leukemia Res., 1995, 19, 303.
20. Luna-Finemen S., Shannon K.M., Langer B.J.: Childhood monosomy 7: Epidemiology, biology and mechanistic implications. Blood, 1995, 85, 1985.
21. Pedersen B., Ellegaard J.: A factor encoded by 7q31 suppresses expansion of the 7q-clone and delays cytogenetic progression. Cancer Genet. Cytogenet., 1994, 78, 181.
22. Stanley W.S., Burkett S.S., Segel B. i wsp.: Constitutional inversion of chromosome 7 and hematologic cancers. Cancer Genet. Cytogenet., 1997, 96, 46.
23. Scherer S. W., Neufeld E.J., Lievens P M-J., Orkin S.H., Kim J., Tsui L-C.: Regional localization of the CCAAT displacement protein gene (CULT 1) to 7q22 by analysis of somatic cell hybrids. Genomics, 1993, 15, 695.
24. Hirst W.J.R., Czepulkowski B., Mufti G.J.: Consistent interstitial chromosomal deletions in myeloid malignancies and their correlations with fragile sites. Cancer Genet. Cytogenet., 1993, 65, 51.
25. Wattel E., Lai J.L., Hebbar M. i wsp.: De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematological and prognostic features? Leukemia Res., 1993, 17, 921.
26. Neuvirtova R., Mocikova K., Musilova J. i wsp.: Mixed myelodysplastic and myeloproliferative syndromes. Leukemia Res., 1996, 20, 716.
27. Greenberg P., Cox C., Le Beau M.M. i wsp.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 1997, 89, 2079.
28. Verma R.S., Triantafillou N.G.: Oncogenetic map of human genome. Cancer Genet. Cytogenet., 1998, 100, 88.
29. Lai J.L., Preudhomme C., Zandecki M. i wsp.: Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia, 1995, 9, 370.
30. Mecucci C., van Orshoven A., Vermaelen K. i wsp.: 11q- chromosome is associated with abnormal iron stores in myelodysplastic syndromes. Cancer Genet. Cytogenet., 1987, 27, 39.
31. Golub T.R., Barker G.F., Lovett M., Gilliland D.G.: Fusion of PDGF receptor B to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell, 1994, 77. 307.
32. Mugneret F., Dastugue N., Favre B. i wsp.: Der(16)t(1;16)(q11;q11) in myelodysplastic syndromes: a new non-random abnormality characterized by cytogenetic and fluorescence in situ hybridization studies. Br. J. Haematol., 1995, 90, 119.
33. Shi G., Weh H.-J., Duhrsen U., Zeller W., Hossfeld D K.: Chromosomal abnormality inv(3) (q21q26) associated with multilineage hematopoietic progenitor cells in hematopoietic malignancies. Cancer Genet. Cytogenet., 1997, 96, 58.
34. Suzukawa K., Parganas E., Gajjar A. i wsp.: Identification of a breakpoint cluster region 3′ of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI 1 gene in acute myelogenous leukemias with inv(3) (q21q26). Blood, 1994, 84, 2681.
35. Wong K.F., Hayes K.J., Leung S., Glassman A.B.: The reltionship between age and karyotypic abnormalities in myelodysplastic syndromes. Cancer Genet. Cytogenet., 1996, 88, 80.
36. Parlier V., van Melle G., Beris Ph. i wsp.: Prediction of 18-monts survival in patients with primary myeldysplastic syndrome. Cancer Genet. Cytogenet., 1995, 81, 158.
37. Mascheck H., Kaloutsi V., Rodriguez-Kaiser M. i wsp.: Hypoplastic myelodysplastic syndrome: incidence, morphology, ctogenetics and prognosis. Ann. Hematol., 1993, 66, 117.
38. Morel P., Hebbar M., Lai J.L. i wsp.: Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia, 1993, 7, 1315.
39. Toyama K., Ohyashiki K., Yoshida Y i wsp.: Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndrome: a multicenter study in Japan. Leukemia, 1993, 7, 499.
40. White A.D., Hoy T.G., Jacobs A.: Extended cytogenetic follow-up and clinical prognosis in patients with myelodysplastic syndrome (MDS). Leukemia Lymphoma, 1994, 12, 401.
41. Jacobs A.: Genetic abnormalities in myelodysplastic syndromes. Cancer Genet. Cytogenet., 1991, 56, 1.
42. Greenberg P.L.: In vitro marrow culture studies in myelodysplastic syndromes. Semin Oncol., 1992, 19, 34.
43. Hirsch-Ginsberg C., Le Maistre A.C., Kantarjian H. i wsp.: RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood, 1990, 76, 1214.
44. Melani C., Haliassos A., Chomel J.C. i wsp.: Ras activation in myelodysplastic syndromes: clinical and molecular study of the chronic phase of the disease. Br. J. Haematol., 1990, 74, 408.
45. Kapelko-Slowik K., Kuliczkowski K., Padua R.A.: Analiza ilościowa genu c-fms u pacjentów chorych na ostre białaczki szpikowe (OBS).
46. Nakagawa T., Saitoh S., Imoto S. i wsp.: Loss of multiple point mutations of RAS genes associated with acquisition of chromosomal abnormalities during disease progression in myelodysplastic syndrome. Br. J. Haematol., 1991, 77, 250.